Next Stop, Don't Block the Doors: Opening Up Access to Clinical Trials Results by 
PLoS Medicine  |  www.plosmedicine.org 1007 July 2008  |  Volume 5  |  Issue 7  |  e160
Editorial
2
008 has been a good year for 
access to research. Effective New 
Year’s Day, both the Canadian 
Institutes of Health Research [1] and  
the Howard Hughes Medical Institute 
[2] require publicly accessible archiving 
of papers published by their grantees. 
Also in January, the European Research 
Council announced its European 
Union–wide open-access mandate 
[3]. In February, the Harvard Faculty 
of Arts and Sciences voted to give 
the University a worldwide license 
to exercise copyright in each faculty 
member’s scholarly articles for the 
purpose of making these articles freely 
available [4]; Harvard Law School 
committed to mandatory free access 
in May [5]. In March, the European 
University Association endorsed open-
access repositories [6], and in April 
the United States National Institutes of 
Health Public Access Policy [7] took 
effect, bringing America’s leading 
sponsor of biomedical research into 
the impressive circle of agencies that 
require archiving of papers resulting 
from the research they fund. Judging 
by the ever-increasing number 
of submissions to PLoS journals, 
authors appear to be voting with 
their manuscripts for open access to 
research.
The year is only half over, however, 
and at least one important milestone is 
still to come. As of September 27, 2008, 
the US Food and Drug Administration 
Amendments Act of 2007 (FDAAA) 
will require that clinical trials results be 
made publicly available on the Internet 
through an expanded “registry and 
results data bank” [8].
Under FDAAA, enrollment and 
outcomes data from trials of drugs, 
biologics, and devices (excluding 
phase I trials) must appear in an 
open repository associated with the 
trial’s registration, generally within 
a year of the trial’s completion, 
whether or not these results have been 
published. The new law is innovative 
in bridging the gap between a clinical 
trial’s registration at inception (now 
an established requirement for 
publication) and the public archiving 
of its final peer-reviewed report. 
For each trial falling within its 
scope, the law requires the posting 
of a table of “demographic and 
baseline characteristics” of the study 
participants, as well as a “table of 
values for each of the primary and 
secondary outcome measures for each 
arm of the clinical trial, including the 
results of scientifically appropriate 
tests of the statistical significance.” 
Safety outcomes must be posted as of 
2009, and further information may be 
required in future years. These are not 
just recommendations; the law imposes 
fines of up to US$10,000 per day for 
noncompliance.
PLoS Medicine and the other PLoS 
journals endorse timely and accessible 
reporting at all stages of clinical drug 
and device development. As we now 
state in our Author Guidelines: “PLoS 
supports the public disclosure of all 
clinical trial results, as mandated for 
example by the FDA Amendments Act, 
2007. Prior disclosure of results on a 
public website such as clinicaltrials.
gov will not affect the decision to peer 
review or acceptance of papers in PLoS 
journals” [9].
We are not alone in favoring such 
availability of results. In January 
2008, the BMJ published an editorial 
supporting FDAAA’s “great leap 
forward for public disclosure” and 
noting that “[t]he BMJ will consider 
disclosed trials and urges other 
journals to do the same…” [10]. In 
May, the Canadian Institutes of Health 
Research convened a meeting of the 
PROCTOR group (Public Reporting 
Of Clinical Trials Outcomes and 
Results) to launch “an international 
dialogue of constituencies interested 
in results reporting” with the goal of 
“contributing toward the development 
of international standards for results 
disclosure” [11]. In June, members 
of the World Health Organization’s 
Registry Platform Working Group on 
the Reporting of Findings of Clinical 
Trials advanced a position that “the 
findings of all clinical trials must be 
made publicly available,” but noted 
that “Although some journal editors 
have acknowledged the changing 
climate around results registration and 
reporting…they may have a conflict of 
interest in that they will probably want 
the key (and potentially most exciting) 
messages from a trial to appear first, 
and perhaps exclusively, in their 
publication” [12].
Indeed, one criterion that editors 
must determine is how much data 
can be publicly presented without 
constituting prior publication—
standard grounds for disqualifying a 
manuscript from consideration. In 
practical terms, this determination 
indicates the extent of a journal’s 
support for public disclosure. In 
2007, prior to the passage of FDAAA, 
the International Committee of 
Medical Journal Editors (ICMJE) 
had announced that its 12 affiliate 
journals would permit very limited 
prepublication presentation of 
results “posted in the same clinical 
trials registry in which the primary 
registration resides…if the results 
are presented in the form of a brief, 
structured (<500 words) abstract  
or table,” and had noted that  
“[r]esearchers should be aware that 
editors may consider more detailed 
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deposition of trial results in publicly 
available registries to be prior 
publication” [13].
How will journals adapt such 
positions in the wake of FDAAA, 
and in light of the need for broader 
international consensus as articulated 
by PROCTOR? In one scenario, 
business interests might drive a 
journal to constrain data disclosure 
by limiting consideration to authors 
whose archived results adhere to 
the narrowest interpretation of the 
law. Concerns about loss of profit 
from reprint sales, advertising, or 
subscription income, or a publisher’s 
desire to control information that 
might become part of a lucrative 
proprietary database may come into 
consideration. But such motivations 
would be difficult to justify on 
principle. The withholding of 
biomedical research results serves 
neither the public interest nor the 
advancement of science. 
Traditionally, journal editors have 
assumed substantial responsibility 
for, and taken a lead in defining, 
the quality of research reports that 
do reach the public. The ICMJE’s 
pivotal role in requiring clinical trials 
registration provides an example of this 
responsibility, as do journals’ rules for 
disclosure of competing interests by 
authors and reviewers. Beyond financial 
concerns, it is therefore appropriate 
that editors consider the effects that the 
availability of results outside traditional 
publication might have. As Zarin and 
Tse have pointed out [14], FDAAA 
promotes transparency by outlawing 
concealment of a trial’s existence or 
results, but does not directly address 
problems arising from flawed study 
design, failure to adhere to ethical 
principles, presentation of fraudulent 
data, or misrepresentation of actual 
results. These matters of research 
quality and interpretation routinely fall 
to editors and peer reviewers to identify 
and, when possible, to correct.
Under FDAAA, will the initial 
reporting instead become the sole 
province of those with the greatest 
financial or personal interest in a 
favorable result, without the benefit 
of dispassionate evaluation? Will 
the public find itself beset by press 
coverage of post-hoc subgroup analyses, 
overgeneralizations of results, or 
improper statistical treatments, slickly 
packaged as medical breakthroughs? 
Or will immediate and universal access 
via the Internet to an ever-increasing 
number of health-savvy readers provide 
a better level of scrutiny? (These savvy 
readers include experienced care 
providers, patient and professional 
organizations, consumer advocates, 
specialty bloggers, health reporters, 
and entire fields of researchers—not 
just the few selected to perform formal 
peer review of a given trial.) Given 
that trials results must now be released 
irrespective of “formal” publication 
in a journal, it surely makes sense to 
ensure that the public dataset for every 
trial contains sufficient information to 
permit objective evaluation of the trial’s 
findings for each prespecified study 
outcome.
In the best case, unfettered access 
by these parties would provide radical 
improvements over the current 
system, in which limited access to 
data hampers systematic review and 
abets disingenuous drug marketing. 
It’s not difficult to imagine a vigorous 
network of skilled evaluators serving 
as watchdogs over posted data that 
have been misrepresented or remain 
unpublished. Perhaps peer-reviewed 
journals will provide a forum for 
publishing independent analyses 
of such datasets. The appearance 
of such articles would mark a full 
circle affirming the contribution of 
formal peer review, but would also 
demonstrate the value of openly 
available results. 
Constraining prepublication data to 
protect the public interest seems wholly 
untenable given the likely benefits of 
entrusting these data to an informed 
public. But will individuals with the 
requisite abilities assume the necessary 
responsibilities? Will universities, the 
news media, or the FDA itself see 
critical evaluation of public data as an 
effort worthy of professional or financial 
reward, or will the task of monitoring 
data quality and interpretation fall 
entirely to volunteers? The details of 
how to maximize public benefit while 
minimizing abuse require careful 
consideration. 
With FDAAA the train leaves the 
station, perhaps before many have 
found their seats. We think it’s going 
in the right direction, but would 
expect some jostling. As we encourage 
colleagues at other journals to fulfill 
the promise of trials registration and 
to support authors who would publicly 
share the results of their research—
even where the law doesn’t require 
it—we also recognize that the debate 
on how best to publicize these results 
is still in its early stages. We therefore 
support PROCTOR’s emphasis 
on global involvement in realizing 
the long-term benefits of this new 
opportunity.  
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